A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report

Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy characterized by a poor prognosis, with a median survival time of approximately 3 to 4 months. In this report, we present a case involving a 59-year-old patient diagnosed with ATC, who experienced swift local recurrence an...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Ming Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544604/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823856577384284160
author Jingjing Chai
Jiaqi Lv
Jian Xiong
Xiuwen Chen
Senyuan Luo
Zhiguo Luo
Zhiguo Luo
Ming Luo
author_facet Jingjing Chai
Jiaqi Lv
Jian Xiong
Xiuwen Chen
Senyuan Luo
Zhiguo Luo
Zhiguo Luo
Ming Luo
author_sort Jingjing Chai
collection DOAJ
description Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy characterized by a poor prognosis, with a median survival time of approximately 3 to 4 months. In this report, we present a case involving a 59-year-old patient diagnosed with ATC, who experienced swift local recurrence and pulmonary metastasis following radical thyroidectomy. Comprehensive Sanger sequencing of the resected tumor tissue revealed no mutations in the TERT promoter or the BRAF V600E gene. The patient exhibited rapid recurrence post-surgery and was deemed unsuitable for immediate surgical intervention. The patient was unable to tolerate chemotherapy; therefore, radiotherapy was administered initially to prevent airway compression resulting from disease progression. During the course of radiotherapy, pulmonary metastasis developed, yet the patient remained intolerant to both chemotherapy and anti-angiogenic therapy. Immunohistochemical analysis revealed a high expression of PD-L1. Whole exome sequencing (WES) indicated a tumor mutation burden (TMB) of 2.98 mut/Mb, microsatellite stability (MSS), and identified 10 missense mutations, 1 nonsense mutation, and 1 frameshift insertion. However, none of these mutations have corresponding targeted therapies. Consequently, we administered tislelizumab as an immunotherapeutic intervention. The patient exhibited significant regression in cervical metastatic lymph nodes and pulmonary metastatic tumors, achieving a sustained remission lasting 14 months, culminating in complete remission, without experiencing any adverse events related to immune checkpoint inhibitors. This case demonstrates the efficacy of second-line monotherapy with an immune checkpoint inhibitor (ICI) for ATC in a patient unable to tolerate chemotherapy and anti-angiogenic anlotinib treatment, thereby offering a viable treatment strategy for ATC patients.
format Article
id doaj-art-4aa57c766bfc4e5790f4f6270c070744
institution Kabale University
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-4aa57c766bfc4e5790f4f6270c0707442025-02-12T07:25:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15446041544604A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case reportJingjing Chai0Jiaqi Lv1Jian Xiong2Xiuwen Chen3Senyuan Luo4Zhiguo Luo5Zhiguo Luo6Ming Luo7Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaCardiovascular Department, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaKey Laboratory of Cancer Therapy Resistance and Clinical Translational Study, Shiyan, Hubei, ChinaDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaAnaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy characterized by a poor prognosis, with a median survival time of approximately 3 to 4 months. In this report, we present a case involving a 59-year-old patient diagnosed with ATC, who experienced swift local recurrence and pulmonary metastasis following radical thyroidectomy. Comprehensive Sanger sequencing of the resected tumor tissue revealed no mutations in the TERT promoter or the BRAF V600E gene. The patient exhibited rapid recurrence post-surgery and was deemed unsuitable for immediate surgical intervention. The patient was unable to tolerate chemotherapy; therefore, radiotherapy was administered initially to prevent airway compression resulting from disease progression. During the course of radiotherapy, pulmonary metastasis developed, yet the patient remained intolerant to both chemotherapy and anti-angiogenic therapy. Immunohistochemical analysis revealed a high expression of PD-L1. Whole exome sequencing (WES) indicated a tumor mutation burden (TMB) of 2.98 mut/Mb, microsatellite stability (MSS), and identified 10 missense mutations, 1 nonsense mutation, and 1 frameshift insertion. However, none of these mutations have corresponding targeted therapies. Consequently, we administered tislelizumab as an immunotherapeutic intervention. The patient exhibited significant regression in cervical metastatic lymph nodes and pulmonary metastatic tumors, achieving a sustained remission lasting 14 months, culminating in complete remission, without experiencing any adverse events related to immune checkpoint inhibitors. This case demonstrates the efficacy of second-line monotherapy with an immune checkpoint inhibitor (ICI) for ATC in a patient unable to tolerate chemotherapy and anti-angiogenic anlotinib treatment, thereby offering a viable treatment strategy for ATC patients.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544604/fullanaplastic thyroid carcinomaPD-1 inhibitorPD-L1 expression levelwhole exome sequencingcase report
spellingShingle Jingjing Chai
Jiaqi Lv
Jian Xiong
Xiuwen Chen
Senyuan Luo
Zhiguo Luo
Zhiguo Luo
Ming Luo
A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
Frontiers in Immunology
anaplastic thyroid carcinoma
PD-1 inhibitor
PD-L1 expression level
whole exome sequencing
case report
title A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
title_full A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
title_fullStr A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
title_full_unstemmed A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
title_short A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
title_sort remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations a case report
topic anaplastic thyroid carcinoma
PD-1 inhibitor
PD-L1 expression level
whole exome sequencing
case report
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544604/full
work_keys_str_mv AT jingjingchai aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT jiaqilv aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT jianxiong aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT xiuwenchen aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT senyuanluo aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT zhiguoluo aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT zhiguoluo aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT mingluo aremarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT jingjingchai remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT jiaqilv remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT jianxiong remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT xiuwenchen remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT senyuanluo remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT zhiguoluo remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT zhiguoluo remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport
AT mingluo remarkableanddurableresponsetotislelizumabtreatmentofananaplasticthyroidcarcinomawithouttargetablegenomicalterationsacasereport